Williams Lewis T.'s most recent trade in Protagonist Therapeutics Inc was a trade of 3,762 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Protagonist Therapeutics Inc | Lewis T. Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 3,762 | 3,762 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Lewis T. Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 2,695 | 7,825 (0%) | 0% | 0 | Common Stock | |
| Protagonist Therapeutics Inc | Lewis T. Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 6,584 | 6,584 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Lewis T. Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 5,130 | 5,130 (0%) | 0% | 0 | Common Stock | |
| Protagonist Therapeutics Inc | Williams Lewis T. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 25,700 | 25,700 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Lewis T. Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Lewis T. Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Arcellx Inc | Lewis T. Williams | Director | 08 Feb 2022 | 2,095,114 | 2,095,114 | - | 0 | Common Stock | ||
| Arcellx Inc | Lewis T. Williams | Director | 08 Feb 2022 | 1,163,886 | 0 | - | - | Series B-1 Preferred Stock | ||
| Arcellx Inc | Lewis T. Williams | Director | 08 Feb 2022 | 931,228 | 0 | - | - | Series B-2 Preferred Stock | ||
| Protagonist Therapeutics Inc | Lewis T. Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 18,000 | 18,000 | - | - | Stock Option (right to buy) | |
| Neoleukin Therapeutics Inc | Lewis T. Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) |